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Alpha (α) initial half-life in a two compartment model, usually representing 
distribution  
AUC  area under the curve 
Beta (β) second decay half-life in a two compartment model, usually representing 
elimination 
Ce  cerium 
CL  clearance 
Cmax  maximum concentration 
ENM   engineered nanomaterial 
iv  intravenous 
ICP-MS inductively coupled plasma mass spectrometry 
MDL  method detection limit 
MRT   mean residence time  
PBPK  physiologically-based pharmacokinetic 
t½  half-life 
Vdss   apparent volume of distribution at steady state 
 
Abstract:  
Objectives: Characterize different sized ceria engineered nanomaterial (ENM) 
distribution in and clearance from blood, compared to the cerium ion, following 
intravenous infusion. Methods: Cerium (Ce) was quantified in whole blood, serum, and 
clot (the formed elements) up to 720 h. Results: Traditional pharmacokinetic modeling 
showed best fit for 5-nm ceria ENM and the cerium ion. Ceria ENMs larger than 5 nm 
were rapidly cleared from blood. After initially declining, whole blood 15- and 30-nm 
ceria increased; results not well-described by traditional pharmacokinetic modeling. The 
cerium ion and 5- and 55-nm ceria did not preferentially distribute into serum or clot, a 
mixture was predominantly in the clot, and 15- and 30-nm ceria migrated into the clot 
over 4 h.  Conclusions: Five-nm ceria may not be readily recognized by 
reticuloendothelial organs. Increased ceria distribution into the clot over time may be 
due to opsonization. Traditional pharmacokinetic analysis was not very informative. 
Ceria ENM pharmacokinetics are quite different from the cerium ion.    
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Current uncertainties in nanoscale material evaluation in biological systems include 
proper/adequate material characterization, the dose metric(s) that best describe and 
predict their effects, and whether they behave like traditional xenobiotics. A key 
component of research quality and standardization with nanoscale materials is their 
physicochemical characterization. The “appropriate” characterization methods are 
currently under intense debate, as is the “best” metric of dose or exposure. Further 
research results that identify the material characterization methods most relevant to 
their biological properties and dose metrics that best predict ENM response will guide 
researchers toward more standard and appropriate methods, increase confidence in the 
results, and generate more consistent results. This is occurring and is expected to 
mature in the next 5 to 10 years. 
 
The ongoing generation of research results by many groups describing the kinetics of 
ENMs will provide much more insight into how ENMs are handled in vivo. The kinetic 
endpoints include absorption (uptake), distribution, biotransformation (and 
opsonization), re-distribution (translocation), and elimination. These appear to be greatly 
influenced by the physicochemical properties of nanoscale materials. As noted in a 
recent review of the pharmacokinetics of carbon-based and quantum dot ENMs, they 
are not amenable to classical pharmacokinetic parameter estimations due to their 
differences from the solution chemistry of their components. Results of the present work 
support this observation, leading to the necessity to adopt or develop other approaches 
to describe ENM pharmacokinetics. It is anticipated that this will occur over the next 5 
to10 years, perhaps utilizing predictive, pharmacokinetic, physiologically-based, or non-






• Nanoscale ceria pharmacokinetics, biodistribution, and clearance pattern cannot 
be predicted from those of the cerium ion.  
• Nanoscale ceria circulation time in the blood of particles too large to be filtered by 
the kidney (> 5 nm) and apparently too small to be readily recognized by the 
reticuloendothelial organs (< 15 nm) is much longer than larger nanoscale ceria. 
• Cubic and polyhedral nanoscale ceria that was 15 nm or greater in diameter was 
very rapidly cleared from circulating blood. The small remaining fraction in blood 
persisted for some time.  
• Nanoscale ceria size and shape influenced its distribution between blood serum 
compared to a blood fraction containing red cells, white cells, and platelets.  
• The results suggest nanoscale ceria undergoes surface chemistry changes in 
blood within hours of its entry, and that these changes are most pronounced with 
15 to 30 nm ceria particles. This may be due to opsonization.   
• The sites of ceria ENM residence in and outside of circulating blood during the 
first several hours after its administration and the physicochemical properties that 
influence this are not well understood. 
• A firm understanding of the rate and nature of ceria ENM association with blood 
proteins and cells and the process(es) of their clearance from blood are needed 
to fully interpret their fate in the vascular compartment. 
• The analysis of nanoscale particle concentration in blood vs. time is not 
amenable to traditional pharmacokinetic analyses. This is illustrated by the 
increase in cerium in blood after ceria ENM iv infusion; an unusual property 
following the iv administration of agents.  Non-classical methods are necessary 
to model and interpret the pharmacokinetics of ENMs. 
  
Introduction: 
There has been much research to develop engineered nanomaterials (ENMs). Polymer 
ENMs are being developed as drug delivery systems [1, 2], and some metal and metal 
oxide ENMs are being developed as therapeutic agents. Human exposure may also 
come from occupational and environmental sources. Little is known about ENM 
distribution or persistence in the vascular system. We were unable to find published 
studies of the distribution of metal or metal oxide ENMs among blood compartments. 
 
To investigate the persistence and distribution of a model ENM in blood we utilized ceria 
(a.k.a.: CeO2, ceric oxide). Numerous studies reported ceria ENM to be neuro- and 
cardioprotective, suggesting it has therapeutic utility in medical disorders caused by 
reactive oxygen species [3-11]. On the other hand, there are reports of ceria-induced 
toxicity associated with increased oxidative stress [12-17]. Nanoscale ceria is a catalyst, 
marketed as a diesel fuel additive, generated during combustion in the Eolys® system 
[101], and is in the walls of self-cleaning ovens. As an abrasive it is used in chemical-
mechanical planarization in electronic circuit manufacture. Nanoscale ceria was 
nominated by the U.S. National Institute for Environmental Health Sciences, NIH, for 
toxicological consideration, including toxicokinetic studies [102]. The Organisation for 
Economic Co-operation and Development Environment Directorate included ceria on its 
priority list of nanomaterials in commerce (or likely to enter into commerce in the near 
term) for measurement, toxicology and risk assessment [103]. However, there are no 
reported studies of the pharmacokinetics of nanoscale ceria other than our report that a 
commercial ~ 30-nm ceria had an initial t½ of ~ 0.125 h [18]. It is vitally important to 
understand the pharmacokinetics of ENMs in relation to their potential therapeutic 
applications and/or toxicity. The pharmacokinetics of carbon-based ENMs and quantum 
dots has been reviewed [19], but much less has been reported for other metal and 
metal oxide ENMs. 
 
Little is known about the influence of size on the distribution in and clearance from blood 
of metal and metal oxide ENMs. We found that the blood cerium concentration was 0.56 
and 1.3 mg/L after a 1 h infusion of 50 or 250 mg/kg of an ~ 30-nm commercial ceria 
ENM to rats [18]. In contrast, 1 h after infusion of 100 mg/kg of an in-house 
manufactured 5-nm ceria ENM it was 370 mg/L [20], suggesting that the rate of metal 
oxide ENM clearance from blood was size dependent. The present study was 
conducted to test this hypothesis.  
 
Another factor that influences the rate of ENM clearance from blood and their 
distribution is their surface chemistry, including charge and surface coating. A zeta 
potential greater than +30 or less -30 mV decreases the potential for agglomeration in 
the medium due to repulsive electrostatic forces [21]. ENMs are often coated with 
polymers such as polyethylene glycol or oxygen-rich ions such as citrate. These coating 
increase ENM hydrophilicity and stabilize ENM dispersions through the electrostatic 
repulsion mechanism, which may reduce their clearance by the reticuloendothelial 
system [22-25]. [Note: do not use the work, solubility, here.]Citrate, an endogenous 
molecule present in the blood and an integral component of the tricarboxylic acid cycle, 
was used in the present study as a ceria surface coating to minimize agglomeration. It 
has been shown that citrate-surface coating of metal/metal oxide ENMs resulted in their 
non-specific attachment to the surface of HeLa cells in vitro and over-coating by humic 
acid and albumin [24, 26, 27].  
 
The present work was conducted to test the hypotheses that the fate of a metal oxide 
ENM in blood is different than its constituent metal and that ENM size and shape 
influence its persistence in and distribution within the major components of blood. We iv 
infused the cerium ion, four sizes of cubic or polyhedral citrate-coated ceria ENMs, and 
a mixture of cubic and rod-shaped ceria to rats. Blood was repeatedly withdrawn up to 4 
h later, and in some cases up to 30 days. An aliquot of each blood sample drawn up to 
4 h after ceria infusion was allowed to clot. By comparison of Ce in whole blood, serum, 
and the clot we could determine pharmacokinetic parameters of ceria distribution in, and 
clearance from, blood. 
  
Materials and methods: 
Cerium chloride heptahydrate (Sigma-Aldrich #228931, 99.9% metal basis), cerium 
nitrate hexahydrate (Sigma-Aldrich # 22350, >99.0%), sodium hydroxide (Fisher #S318-
1, certified ACS pellets), ammonium hydroxide (Fisher # 3256, ACS, 28-30%), 
hexadecyltri-methylammonium bromide (CTAB, Sigma-Aldrich #H9151, ~99.0%), 
deionized ultra filtered water (DIUF, Fisher #W2-20), and citric acid monohydrate (EMD 
Chemicals Inc # CX1725-1, GR ACS) were used without further purification.  
 
Ceria ENM synthesis 
Five nm ceria ENM was synthesized as described [28]. Typically a 20 ml aqueous 
mixture of 0.5 M (0.01 mol) ceria chloride and 0.5 M (0.01 mol) citric acid was added to 
20 ml of 3 M ammonium hydroxide. The latter was in excess of that needed for 
complete reaction of the cerium chloride to cerium hydroxide. The final product was an 
un-buffered ceria dispersion with a pH of 8 to 9. After stirring for 24 h at 50°C, the 
solution was transferred into a Teflon-lined stainless steel bomb and heated at 80°C for 
24 h to complete the reaction. The cerium concentration in samples taken from the top 
and bottom of two ceria dispersion samples that were un-disturbed for > 2 months were 
within 2.5% of each other, demonstrating dispersion stability. Settling of the 5 nm ceria 
dispersion was not observed over at least three months and dynamic light scattering 
estimates of 5 nm ceria particle size distributions were similar to those obtained initially.  
The dispersed ceria ENM was infused intravenously without any further treatment. 
 
Fifteen nm ceria ENM was synthesized using a hydrothermal procedure [29]. In a typical 
procedure, 2 ml ammonium hydroxide was drop-wise added into 20 ml aqueous mixture 
of 1.5 mmol cerium nitrate and 0.5 mmol CTAB and kept stirring for 0.5 h to form a 
brown emulsion. The emulsion was transferred into a Teflon-lined stainless steel bomb 
and heated at 120 °C for 24 h to complete the reaction. The fresh product was washed 
with water three times to remove free cerium, dialyzed three times with fresh citric acid 
aqueous solution, and dried at 55 °C for 24h. The final 15 nm citrate modified ceria 
powder was re-dispersed into water to prepare a ~5 wt% aqueous suspension. The pH 
of the resulting un-buffered ceria dispersion was 3.5. 
 
Thirty nm ceria was synthesized using a hydrothermal approach [30]. Generally, 20 ml 
aqueous mixture of 1 mmol cerium nitrate and 105 mmol sodium hydroxide was stirred 
for 0.5 h to get a milky suspension. The suspension was transferred into a Teflon-lined 
stainless steel bomb and heated at 180 °C for 24 h. After the hydrothermal treatment, 
fresh white precipitates were washed with deionized water three times and then ethanol 
three times to remove the free cerium and organic impurities. Then the wet precipitates 
were dispersed into 0.05 M citric acid aqueous solution with stirring overnight, followed 
by washing with water 5 times.  The resulting dispersion had a pH of 3.9. 
 
The mixture of 30 nm cubic ceria ENMs with nanorods was synthesized using a 
hydrothermal method [31]. Typically, 0.9 mmol cerium nitrate was dissolved into 15 ml 9 
M sodium hydroxide solution with stirring for 0.5 h.  The suspension was transferred into 
a Teflon-lined stainless steel bomb and heated at 140 °C for 48 h. After the 
hydrothermal treatment, fresh precipitates were separated by centrifugation, and 
washed with deionized water three times. The wet precipitates were dispersed into 0.06 
M citric acid aqueous solution overnight, washed with water for several times until the 
final suspension had a pH around 7.  
 
Fifty-five nm ceria ENM was synthesized by a method [32] modified with controlled 
thermal treatment to achieve the desired ceria particle size (unpublished results). It was 
re-dispersed in citrate solution and washed three times in doubly distilled water to 
remove free cerium and citrate. The resulting dispersion had a pH of 7. 
 
Ceria characterization 
The morphology, crystallinity, and phase purity of each citrate-coated ceria ENM were 
determined in our laboratories using high resolution-transmission electron 
microscopy/scanning transmission electron microscopy and X–ray diffraction analyses. 
Primary particle size distributions were determined by TEM analysis [33]. The 
crystallinity of all ceria ENMs were determined by XRD (Siemens 5000 diffractometer). 
Particle size distributions in aqueous suspension were determined using dynamic light 
scattering (90Plus Nanoparticle Size Distribution Analyzer, Brookhaven Instruments 
Corp, Holtsville, NY). To indicate the stability of the ceria dispersion when infused into 
the rat, the zeta potential was measured for each ENM (except the mixture of ceria 
nanoparticles and nanorods) using a Zetasizer nano ZS (Malvern Instruments, 
Worchestershire, UK). The Zetasizer estimates the surface charge of nanoparticles 
based on the assumption that the correlations are generated from spheres, but 
nanorods have an elongated axis and different mobility from spherical nanoparticles; the 
instrument therefore often fails to provide consistent and accurate estimation for 
nanorods and mixtures that include rods. Since all of the ceria ENMs had hydrodynamic 
diameters < 200 nm, the Hückel approximation was used to calculate zeta potential 
from electrophoretic mobility. To estimate the extent of citrate surface coating each of 
the ceria ENMs was washed at least three times with water before drying. As separation 
of the 5 nm ceria by centrifugation required ~12000 rpm for 12 h due to their small size, 
they were agglomerated by decreasing the pH to 4, enabling centrifugation.  
Thermogravimetric analysis (Perkin-Elmer TGA7 Analyzer) was then performed to 
investigate the weight loss of citrate-coated ceria NPs over the temperature range of 
150 to 300°C under which decomposition of citric acid occurs. The extent of citrate 
surface coating was estimated based on the assumption that all the ceria NPs were 
spherical and had uniform size. The free cerium concentration in the ceria dispersions 
of the unwashed 5 nm ceria and each of the washed ENMs was determined using 
Amicon Ultra-4 centrifugal 3000 molecular weight cut-off filter devices and centrifugation 
at 3000 g to obtain filtrate, which was analyzed for cerium by ICP-MS. 
 
Animals 
Data were obtained from 101 male Sprague Dawley rats, weighing 325 ± 30 g (mean ± 
SD), that were housed individually in the University of Kentucky Division of Laboratory 
Animal Resources facility. All animal studies were approved by the University of 
Kentucky Institutional Animal Care and Use Committee. The research was conducted in 
accordance with the Society of Toxicology’s Guiding Principles in the Use of Animals in 
Toxicology (http://www.toxicology.org/ai/air/air6.asp).  
 
Cerium ion and ceria ENM administration 
Rats were prepared with 2 cannulae, surgically inserted into femoral veins under 
ketamine/xylazine anesthesia, which terminated in the vena cava, and were connected 
to infusion pumps via a flow-through swivel. This enabled conduct of the study in the 
awake, mobile rat. All samples were sonicated to ensure dispersion prior to 
administration. The day after cannulae implantation the un-anesthetized rat was infused 
via the longer cannula with cerium ion (as the chloride), a ~ 5% ENM dispersion in 
water, or water. A pilot study was conducted with the cerium ion and each of the ceria 
ENMs to determine tolerability following iv infusion. A 100 mg cerium ion/kg infusion 
was lethal. Rats were infused with ~250 or 175 mg/kg of the 5 nm ceria; 3 of 8 died. A 
dose of ~250 mg of the 15 nm ceria/kg was tolerated. Infusion of 100 mg/kg of the 30 
nm ceria resulted in some evidence of mild distress (tachypnea, skittish behavior, and 
not resting well).  Dyspnea and lethargic were seen in rats given 250, 100 or 78 mg of 
the 55 nm ceria/kg. Therefore the target doses were 100 mg/kg for the 5, 15, and 30 nm 
ceria and 50 mg/kg for the 55 nm ceria ENM and the cerium ion. ICP-MS analysis of 
cerium in replicate samples of the dosed materials showed the doses to be 70 to 100% 
of the target doses. Each was infused over 1 h, except for the cerium ion that was 
infused over 2 h. Control rats received water adjusted to the pH of the paired ceria ENM 
or cerium ion.  To compensate for the iv administration of a considerable volume of 
grossly hypotonic infusion, concurrent iv infusion of an equal volume and rate of 1.8% 
sodium chloride in water was delivered into the second, shorter, cannula. Each fluid was 
delivered at ~ 0.6 ml/h.  
 
Sample collection  
After the infusion, 0.6 ml blood was withdrawn at 0.167, 0.5, 0.75, 1, 2 and 4 h from the 
cannula that had not delivered ceria from 3 rats that had received infusion of the cerium 
ion, 6 that received the 30 nm ceria ENM, and 5 that received the 5, 15, 55 or 30 nm 
ceria cube + rod ENM. The blood sample was immediately separated volumetrically into 
two 0.3 ml aliquots to enable determination of Ce in whole blood in one and in the 
serum and clot fractions of the other. A blood clot is formed by platelets and blood 
proteins, including fibrin, and traps the blood’s red and white cells. It may have some 
serum trapped in it; therefore the clot fraction may over-estimate the percentage of Ce 
associated with cells. To determine the distribution of Ce in the serum and clot fractions 
the 0.3 ml sample of whole blood was allowed to clot at room temperature, the clot 
given time to contract, and serum withdrawn into a digestion vessel. The clot was 
withdrawn and placed in another digestion vessel and the remaining serum added to the 
serum sample. This enabled determination of the mass amount of Ce in the two major 
compartments of blood; serum and, from the clot fraction, association with the formed 
elements (red cells, white cells and platelets). This approach was taken to avoid 
centrifugation to generate the serum sample because we found that centrifugation at 
1600 g for 10 min, as used to generate serum, resulted in loss of ~ 75% of a 30-nm 
ceria ENM from the serum sample [18].  
 
Blood was also obtained from some rats 20, 168 (1 week) or 720 h (1 month) after ceria 
ENM administration.  An equal volume of saline was infused after each blood 
withdrawal to replace the fluid volume. Blood was obtained at termination of all rats.  
 
Cerium analysis: 
To determine Ce in whole blood the sample was transferred into a 55 ml TFM 
(polytetrafluoroethylene) digestion vessel (CEM) to which 6 ml trace-metal grade nitric 
acid and 3 ml 30% H2O2 were added, digested in a CEM MARS Xpress microwave at 
180 °C for 10 min to convert all ceria to dissolved Ce4+, diluted with 18 MΩ water to 50 
ml, and subsequently further diluted dependent on the Ce concentration.  
Cerium concentration was determined in whole blood, serum and clot by ICP-MS 
(Agilent 7500cx, Santa Clara, CA, U.S.). Following ceria ENM administration, Ce 
concentration is believed to reflect the Ce in ceria ENM because ceria ENMs are quite 
inert and persist as an ENM in the rat for months [34], and the Ce levels in non-Ce 
treated rats is very low. We determined a method detection limit (MDL) of Ce for blood 
and serum samples of 0.018 mg/L [18]. No samples in this study had Ce concentrations 
below this MDL. Seven samples, containing whole blood, serum or clot, were analyzed 
in duplicate and were spiked with 8.3 ng Ce/ml. Results of duplicate analysis showed a 
range of 0 to 4% between the two determinations. Recovery of the Ce spike ranged 
from 93 to 114%, averaging 105%.  
 
Data analysis and statistics: 
Blood, serum and clot Ce concentrations were normalized to an infusion dose of 100 
mg ceria/kg for all rats, based on determination of the actual Ce content of the infusions 
by ICP-MS analysis, and because a few materials were given at doses other than 100 
mg/kg, as noted above. This enabled direct comparison of results from the cerium ion, 
ceria ENM sizes, and shapes. Outliers, identified using the Grubbs test, were not 
included in the data analysis. Four percent of the 600 whole blood, serum and clot 
samples were outliers by this test. 
 
Pharmacokinetic modeling. Non-compartmental and compartmental analyses of the 
whole blood Ce concentration vs. time results were conducted using WinNonLin, a 
pharmacokinetic analysis program (Pharsight®, St. Louis, Missouri). For non-
compartmental analysis, AUC (h*mg/L), Cmax (mg/L), half life (t1/2, h), and mean 
residence time (MRT, h) were calculated. The squared correlation of distances (Rsq) 
and correlation between time (X) and Ce concentration (Y) (Corr-XY) were used to 
measure the goodness of fit. For compartmental analysis, one and two compartments 
were evaluated to determine the best model fit. AUC (h*mg/L), Cmax (mg/L), half life (t1/2, 
h), mean residence time (MRT, h), clearance (CL, ml/h/kg) and apparent volume of 
distribution at steady state (Vdss) were calculated. Various weightings were evaluated, 
including 1, 1/y (y: ceria concentration, which weights higher values more heavily), 1/y2 
(which weights lower values more heavily), 1/predicted concentration (iterative 
reweighting), and 1/predicted concentration2. Goodness of fit was based on visual 
inspection, weighted corrected sum of squares, sum of square residuals, weighted sum 
of square residuals, random distribution of residuals, Akaike’s information criteria, and 
Swartz criteria. The initial estimates for model parameters were calculated as below.  
The semi-logarithmic plots of blood concentration vs. time data showed the one or two 
compartment kinetics model as C(t) = Re−λt and C(t) = R1e−λ1t + R2e−λ2t, respectively.  
𝑅𝑅1 and 𝑅𝑅2 represent intercepts on the concentration (Y) axis of the back-extrapolated 
initial and terminal phases and λ1 and λ2 = the initial and terminal slopes. As blood 
sampling began after completion of the infusion, the iv bolus case was used. 
A = Divλ
kο�1−e−λt�
R was used to correct the infusion intercept values for the one 
compartmental analysis and A1= Divλ1kο�1−e−λ1t�R1 and A2=
Divλ2
kο�1−e−λ2t�
R2  were used in the two 
compartment model.  Div is the infusion dose, kο  is the infusion rate. V1= DivA1+A2  was used 
to calculate the volume of the central compartment. The micro rate constants were 
determined as k21= λ2×A1+λ1×A2A1+A2 ;  k10=
λ2×λ1
K21
; and k12=λ1 + λ2 − k10 − k21.  k12 and k21 
represent the rate constants between central and peripheral compartment, and k10 is the 
elimination rate constant from the central compartment.  The elimination half-lives (t1/2) 
were calculated as t1/2λ1 =0.693/λ1 and t1/2λ2 =0.693/λ2. One-way ANOVA, followed by 
Tukey’s multiple comparison tests (Prism 5.02 software, GraphPad, San Diego, CA), 
was used to test for significant differences in pharmacokinetic parameters among the 6 
treatment groups.   
 
Quality analysis of the WinNonLin coefficients was conducted by determining whether 
the ratio of the coefficient estimate to its average standard error was greater than the 
appropriate p value < 0.05, using a two-tailed Student’s t-test (3.18 for n = 3, 2.78 for n 
= 4), Excel and Systat.  The results showed that the pharmacokinetic parameter 
estimations using WinNonLin were acceptable for only the cerium ion and the 5-nm 
ceria ENM. Two factors contributing to this were 1) that less than 2% of the dose of the 
other 4 ENMs was circulating in the blood when the first sample to estimate the 
pharmacokinetic parameters was obtained (0.167 h after completion of the infusion), 
and 2) the Ce concentration increased in blood from 0.167 to 4 h after infusion of the 
15- and 30-nm ceria, which is not the elimination behavior for typical pharmacokinetic 
models. Therefore, the pharmacokinetic data for ceria ENMs was compared directly to 
that of the cerium ion, which is known to follow typical pharmacokinetic elimination 
models.  
 
Ratio of Ce concentration in whole blood following infusion of ceria ENMs vs. the cerium 





R = R0 ⋅ exp −α ⋅ t( ) met the t-test criterion, then the trend was described by an apparent 
first order process. 
 
Ce partitioning between serum and clot. The quality of the data describing the 
partitioning of Ce between the serum and clot fractions was screened using mass 
balances. The total mass of cerium (or ceria) in the whole blood sample should equal 
the sum of the cerium masses in the serum and clot phases. The cut-off for mass 
material balance screening was taken to be ± 30%. If the sum of the masses of Ce in 
the serum and clot phases was < 70 or > 130% of that in the mass in the whole blood 
sample, the partitioning data were not used in the analysis or shown in the figure. No 
other screening analyses, such as outlier evaluation, were applied.  The partitioning of 




Particle morphologies are shown in Figure 1. Panel D in Figure 1 is part of a larger 
image that shows the diameter and length of the rods in the mixture of 30-nm cubic and 
rod ENMs were ~ 10 nm and 2 µm, respectively. The shape, surface area, zeta 
potential in water, and estimated extent of the ENM surface that was coated with citrate 
are shown in Table 1. All of the ceria ENMs had face-centered cubic (FCC) crystal 
structures with the same Miller indices of (111), (220) and (311), and with lesser 
presence of (200), (222) and (400), based on XRD crystal structure linked to known 
morphology. The 55 nm ceria had the lowest surface coating of citrate and a lower 
absolute surface charge (-31.5mV) than the other ENMs. The unwashed 5 nm ceria 
ENM had 11.6 ± 0.3% free cerium in the dispersion. The washed ceria ENMs were 
found to contain << 1% free cerium. 
Ten min (0.167 h) after completion of the cerium ion or 5-nm ceria ENM infusion ~ 14 
and 32% of the Ce remained in the circulating blood, respectively. This was calculated 
from the measured blood Ce concentration compared to the Ce dose, based on the iv 
infusion of 100 mg ceria/kg into the rat’s vascular system (~ 7% of its body volume), 
which would introduce ~ 1163 mg Ce/l blood. In contrast, the 15-, 30- and 55-nm ceria 
and mixture of 30-nm cubic + rod ceria were rapidly removed from circulation, so that 
0.167 h after their infusion ≤ 2% was in blood (Figure 2).  
 
Pharmacokinetic models were constructed using whole blood Ce concentrations from 
each individual rat’s results. Non-compartmental models showed the best fits for the 
cerium ion (Rsq 0.94 ± 0.08, Corr XY = 0.97 ± 0.04) and 5 nm ceria ENM (Rsq 0.89 ± 
0.06, Corr XY = 0.94 ± 0.03).  However, 15, 30 cubic, 30 cubic + rods, and 55 nm ceria 
ENMs were poorly fitted by non-compartmental modelss. One and two compartment 
models showed the Ce concentrations in blood obtained 0.167 h to 1 week after cerium 
ion infusion and 0.167 h to 30 day following infusion of 5-, 15-, and 30- nm ceria ENMs 
were best fit by two compartmental models (biexponential decay). For the mixture of 30-
nm cubic + rod ceria and the 55-nm ceria ENMs, for which modeling was based on 
results to 4 h after their infusion, the one compartment model provided the best fit. 
 
Table 2 summarizes the pharmacokinetic parameters. Compartmental analysis showed 
the cerium ion to have a greater AUC than the ceria ENMs, a higher Cmax compared to 
the ≥ 15 nm ENMs, and a smaller Vdss than all of the ENMs. Surprisingly, the 15- and 
30-nm cubic ceria materials showed increasing blood concentrations over the period 0 
to 4 h after infusion, with estimated half-lives of this process of ~ 4 and 2.7 h, 
respectively (Figure 2). Since conventional elimination models are always monotonically 
decreasing in solute concentration, the WinNonLin fits were poor and the 15 and 30 nm 
ceria ENMs model coefficients did not meet the Student’s t-test criteria for quality (the 
average standard error was often larger than the estimated value of the coefficient).  
With the exception of the 5-nm ceria ENM, the pharmacokinetic results are based on < 
2% of ceria dose that was remaining in the blood 0.167 h after completion of the ceria 
infusion, therefore the pharmacokinetic parameter estimates describe only a small 
fraction of the dose of these ENMs.  The two-compartment models for each of the rats 
that received cerium ion or 5-nm ceria ENM infusions fit the data very well based on 
visual inspection, weighted corrected sum of squares, sum of square residuals, 
weighted sum of square residuals, random distribution of residuals, Akaike’s information 
criteria, and Swartz criteria.  
 
Figure 3 shows the ratio of the whole blood Ce concentration after infusion of 5-, 15-, 
30-, and 55-nm ceria ENMs vs. the cerium ion.  The ratio, R, for 5 nm ceria ENM could 
be modeled either by a power law dependence,
 
R = R0 ⋅ t
d (R0 is a constant and d is the 
power exponent for time t), or an exponential dependence, 
 
R = R0 ⋅ exp(d ⋅ t)(R0 is the 
Arrhenius-type factor and d is the process rate constant) for each of three animals. 
Trend lines are shown for the power law dependence (Figure 3, top panel) with d ~ -0.8. 
Five-nm ceria ENMs are fitted by two-compartment models and their concentrations 
have apparent links to those of cerium ions, but with different time dependencies. Over 
the time period, 0 to 4 h after infusion, it was cleared faster than the free ion. On the 
other hand, R values for both 15 and 30 nm ceria increased over the 0 to 4 h time 
period and their exponential coefficients were similar (d = 0.41 h-1 and d = 0.45 h-1, 
respectively). The R value of 55 nm ceria showed no strong trend. 
 
The Ce mass balance for cerium ion, calculated by comparing the cerium in the serum 
plus clot samples to the cerium in whole blood, averaged 98 ± 7% over all samples.  For 
the 5-nm ceria ENM, the average mass balance was 83 ± 44%; 5 out of the total of 30 
values from the 6 sample times were below the cutoff of 70% mass balance. These 
ranged from 16 to 31% and were obtained 120 or 240 min after the ceria infusion, at a 
time when Ce concentrations had decreased to an average of 8 and 0.4 microgram Ce 
in the serum prepared from the 0.3 ml of blood. They were not used in the data 
analysis. For the remaining 25 values, recovery was 93 ± 40%. For the 15-, 30-, and 55-
nm ceria ENMs, 17, 16 and 11 of the 18 values from 3 of the rats met the material 
balance quality control criteria and were used in the data analysis, respectively. For the 
30-nm ceria cubes and rods mixture, 12 values from 2 rats met the material balance 
quality control criteria and were used in the data analysis. 
 
Figure 4 shows the ratio of Ce distribution in blood serum vs. whole blood from 0.167 to 
4 h after completion of the cerium ion or ceria ENM infusions. The complement to this is 
the ratio of Ce in the clot (associated with the red and white cells and platelets) vs. 
whole blood fraction (not shown). The ratio of Ce in serum vs. whole blood shows its 
distribution between blood serum and (the clot fraction). Blood samples taken from 0 to 
4 h after infusion showed that the cerium ion, 5-, and 55-nm ceria ENMs did not 
preferentially distribute into either the blood serum or clot (containing red, white cells 
and platelets); there was no consistent time dependence of the ratio for all animals. The 
30 nm cubic + rod mixture preferentially distributed to the clot fraction over a similar 
period, also with no consistent time dependence of the ratio for all animals. However, 
serum/clot partition data for 15- and 30-nm ceria showed that these ENMs migrated into 
the clot fraction, and that partition ratio ceria in the clot increased with time. Two of the 
rats that received 15 nm and 4 that received 30 nm ceria showed a statistically 
significant increase of Ce associated with the clot fraction. 
  
Discussion: 
The crystal structure of the ceria ENMs was as expected because the fluorite structure 
is the only one for crystalline CeO2.  The citrate coating was least dense on the 55 nm 
ceria, suggesting it would be the most likely of the ENMs test to agglomerate in 
aqueous dispersion; a problem that was observed during its administration requiring 
frequent agitation of the dispersion to prevent it from occluding the infusion line. 
Although nearly 12% of the total cerium in the 5 nm ceria ENM was free cerium in the 
aqueous phase, comparison of the results after infusion of the 5 nm ceria ENM, the 
cerium ion, and the other ceria ENMs shows the free cerium cannot account for the 
differences between the 5 nm and the larger ENMs. 
 
In the present study ~ 14% of the cerium ion remained in the blood 0.167 h after 
completion of a 1 h iv infusion. In a previous report Ce was determined in blood from 1 h 
to 3 days following its iv administration as the chloride to mice and rats; however, the 
author did not conduct a pharmacokinetic analysis of the results [35]. Using WinNonLin 
to conduct pharmacokinetic analysis, non-compartmental and compartmental 
calculations of the Bjondahl results [35] showed similar AUC, MRT, Cmax, and CL 
results. The non-compartmental half-life (10 h) was the same as the terminal half-life 
obtained with a two compartment model, which best fit the data for compartmental 
analysis. The initial half-life of the Bjondahl results (~ 3 h) was longer than we obtained 
(0.6 h) because our study included samples taken as early as 10 min, whereas the first 
sample in the Bjondahl study was obtained at 1 h.  
 
Ten min after completion of the iv infusion of ceria ENMs, ~ 32% of the 5-nm ceria but < 
2% of the larger ceria ENMs were present in the blood. The greater extent of citrate 
coating on the 5-nm ceria (and therefore its greater hydrophilicity) may have contributed 
to this. However, we do not know how long the citrate persisted on the surface of the 
ceria ENM or if was covered (opsonized) by proteins. The rapid clearance of 
metal/metal oxide ENMs from blood has been reported previously. 
 
Little has been reported about the fate of systemic cerium, other than it is very slowly 
eliminated, primarily in bile, resulting in prolonged retention in mammals, primarily in the 
liver and skeletal system [36, 37]. Our pharmacokinetic results showed that the cerium 
ion had a smaller Vdss than the 5-nm ceria ENM. It also showed less retention in 
reticuloendothelial tissues, but more in the lung [34]. All the ceria ENMs showed a large 
Vdss indicating great distribution in tissues, consistent with the intracellular 
agglomerations we have seen, especially in reticuloendothelial cells. Ceria ENMs have 
been seen in the cytoplasm of brain cells, phagosomes of macrophages, vesicles of 
lung fibroblasts, spleen red pulp, Kupffer cells, hepatocytes and mesangial cells [18, 20, 
38-41]. Thirty days after ceria ENM infusion the greatest concentration was seen in the 
reticuloendothelial tissues, including liver and spleen [18, 20, 42]. It was reported that 
lung, heart, and brain cerium did not decrease over 6 months following iv ceria ENM 
dosing [39].  A study with the 30-nm ceria ENM used in the present study showed no 
significant decrease of ceria in 14 tissues up to three months after iv administration. The 
highest concentrations were in reticuloendothelial tissues (spleen, liver and bone 
marrow), followed by the lung, then other sites [34].  We are not aware of any reports of 
ceria uptake into red or white blood cells or platelets other than our prior finding 
suggesting a small amount of a 30 nm ceria ENM might have entered red blood cells 
after 1 h in vitro [18]. It is unclear if the ceria ENMs would ever reach a constant blood 
level. Up to the times studied in the present report, there was generally a decrease of 
blood cerium. Given the persistence of ceria in the rat, one might expect a steady state 
to be reached. However, 90 days after ceria infusion blood cerium concentration was 
higher than earlier times [34].  
 
The cerium ion was equally distributed between serum and clot fractions. A previous 
study reported that 2 h after iv cerium ion administration ~ 28% of the cerium in the 
blood was in cells and 72% in serum [43], similar to results in the present study that 
showed ~ 70% in the serum fraction at 2 h. The distribution of ceria ENMs between 
serum and clot varied with size and surface chemistry. The 5-nm ceria was evenly 
distributed within the serum and clot fractions. We previously observed small 
agglomerations of the 5-nm ceria in serum, presumably associated with proteins, and 
agglomerations associated with the extracellular side of the erythrocyte cell membrane 
after 1 h of incubation of the ceria in blood [20]. The ability of ENMs to enter 
erythrocytes, a non-phagocytic cell, has been observed for 78 nm polystyrene, 25-nm 
gold, and 22-, 25- and 80-nm titania ENMs [44-46].  However, we are not aware of any 
studies of ceria ENM or other metal/metal oxide ENMs entry into white blood cells or 
platelets.  
 
Although the extent of citrate coating might be expected to influence the fate of ceria 
ENMs in vivo, the present results show no clear trends between the extent of citrate 
surface coating and ceria ENM distribution between serum and the clot fraction initially, 
or over time.  For the cerium ion, and 5- and 55-nm and the mixture of 30-nm cubic + 
rod ceria ENMs, we were unable to identify any trends in the percentage of Ce in the 
serum vs. time.  
 
The blood levels of the 15- and 30-nm ceria ENMs increased over the 4 h after their 
infusion. As they were given by the iv route, this suggests a re-distribution of the ENM 
over time.  Redistribution of ENMs has been previously recognized and discussed, e.g.  
[47]. An increase of ENM in blood within the first 2 h after iv administration has been 
reported, although the increases appear to be within the variability of the reported 
measure of the quantum dots in plasma or blood and neither report discusses the 
increase [48, 49]. The increase we saw may be influenced by opsonization and/or 
distribution into and out of a non-central compartment, such as the lymphatic system, as 
noted by [50]. We also observed that the distribution of the 15- and 30-nm ceria ENMs 
within blood compartments changed over the 4 h after completion of their infusion, when 
they became more associated with the cells in the clot fraction. These results suggest 
their surface chemistry changed during that period, which may be due to dissociation of 
the citrate, association with proteins or blood cells, and/or cell entry and release. 
Nanoscale materials are rapidly coated with plasma proteins and other circulating 
substances, which create a corona around the ENM, increasing their hydrodynamic size 
[51, 52]. It has been shown that citrate-coated ENMs bind to the surface of cells [24] 
and can become opsonized with albumin [27].  We speculate that the increase of the 
15- and 30-nm ceria ENMs in circulating blood and migration toward the clot fraction 
during the first 4 h after their iv infusion is due to distribution out of, then back into, 
circulating blood, perhaps associated with opsonization. This might be due to initial 
accumulation in blood vessels or adsorption onto the luminal surface of vascular 
endothelial cells, followed by opsonization and re-circulation in blood. However, we 
would not anticipate extensive accumulations of ceria blocking the vasculature in the 
absence of cardio- and cerebrovascular incident (MI and stroke) which we have not 
observed in these rats that generally tolerated the target doses well.  Or the ceria ENMs 
may have distributed outside of the vascular compartment, such as entrapment by 
reticuloendothelial organs followed by their release them back into blood, or entry into 
the lymphatic system, that drains into the cardiovascular system. Particles up to 50 nm 
are able to rapidly enter the lymphatic system [53, 54]. From the results of the present 
study we do not have evidence of the origin of the ceria ENMs that re-entered 
circulating blood during the first 4 h after their infusion. However, we have seen a net 
migration of Ce following 30-nm ceria ENM administration from liver to spleen from 1 to 
20 h after its infusion [55] and into lung over 90 days, consistent with re-distribution of 
this ENM over time [34]. As > 98% of the ceria dose was no longer in circulating blood 
when we started blood sampling 10 min after completion of the ceria infusion, the long 
terminal half-life and MRT and large Vdss for the 5, 15 and 30 nm ceria ENMs, based on 
blood levels to 30 days, may describe the very small fraction of the ENMs that had not 
yet distributed out of blood and/or ceria re-distributing among storage sites. This 
speculation is based on the retention of very large percentage of the ceria ENM dose for 
a long time in the rat and evidence we (and others) have of re-distribution among sites 
over time. Similarly, there may have been some re-distribution of the 5 nm ceria which 
was not seen above the much higher level of ceria remaining in blood from the infusion 
during the first 4 h after its infusion.  
 
The non-compartmental analysis could not estimate some of the pharmacokinetic 
parameters for the 15 and 30 nm ceria ENMs probably because of the ceria 
concentration increase at the first 4 h.  Due to the lack of prior studies of metal and 
metal oxide ENMs in blood, further studies of citrate-coated ceria ENMs are necessary 
to better understand their fate in the vascular compartment, including the stability of the 
citrate coating; their interaction with cell membranes; and the rate, extent and character 
of protein association.  
 
The mean residence time (MRT) typically indicates the average time molecules stay in 
the body.  In our study, the MRT indicated how long ceria ENMs remained in blood, not 
in the tissues, because MRT is derived from measurement of ceria (as Ce) in blood [56]. 
It has been previously noted that the blood half-life of an ENM may be short despite 
prolonged body persistence, due to reticuloendothelial system entrapment and other 
processes not typical of small inorganic and organic molecules [19]. Non-compartmental 
and compartmental analyses produced quite different MRT results, although the trends 
among the tested materials are similar across analysis. The lower MRT values with the 
non-compartmental analysis may be due to its tendency to underestimate MRT [57].  
Knowing that there are persistent accumulations of ceria ENMs in multiple organs 
suggests the MRT results from the compartmental analysis more closely reflects the 
whole body residence time of ceria ENMs. The results of the present pharmacokinetic 
calculations that one can have the most confidence in are those obtained following 
infusion of the cerium ion and the 5-nm ceria ENM, due to the very rapid clearance of 
the larger ENMs from circulating blood and the rise in Ce concentration over 4 h 
following 15- and 30-nm ceria ENM infusion. Although the results obtained with the 
cerium ion and 5, 15 and 30 nm ceria ENMs clearly show two compartments, the values 
for the second compartment do not have a high degree of precision due to the limited 
number of data points on which they are based. 
 
It has been previously noted that some of the properties of ENMs, e.g., opsonization, 
adhesion, and phagocytic uptake, may differ from small organic molecule disposition for 
which pharmacokinetic modeling programs such as WinNonLin were created [19]. 
Pharmacokinetic and PBPK approaches have been used to model ENM distribution 
among tissues and blood [58, 59]. Most nanomaterials do not exhibit ADME profiles 
typical of drugs [60], e.g. they are rapidly cleared from the blood, not metabolized, and 
not rapidly eliminated, unless small enough to be filtered by the renal glomerulus. It has 
been recognized that the toxicokinetics of ENMs are unlikely to follow the “rules” of 
current approaches [61, 62]. Further work is needed to develop a pharmacokinetic 
model to predict the time-dependent changes of ceria ENM distribution in tissues and 
blood.  
 
There is considerable literature on the pharmacokinetics of polymer ENMs due to the 
extensive research in developing them as drug delivery systems. Much less is known 
about the pharmacokinetics of metal and metal oxide ENMs; particularly their 
distribution, residence time, and rate of clearance from the vascular compartment. The 
present study informs about the effects of ENM physicochemical properties on 
distribution and clearance from blood. The results show ceria ENMs have a 
biodistribution and clearance pattern which cannot be predicted from the cerium ion. 
This may be due to the very different physicochemical properties of the cerium ion and 
ceria ENMs.  
 
Conclusions: 
To better understand the fate of ceria as a model ENM we compared the distribution 
within, and rate of clearance from, blood of four different sizes of cubic or polyhedral 
ceria nanoparticles, a mixture of cubes and rods, and the cerium ion after iv infusion into 
rats. Table 3 summarizes the main findings of the present study. The kinetics and 
distribution of the cerium ion did not predict those of the ceria ENMs. A 5-nm ceria 
ENM, which was very resistant to agglomeration and settling in vitro, was cleared much 
more slowly from blood than larger ceria ENMs, presumably because it was too large to 
be cleared by glomerular filtration and perhaps too small or too hydrophilic to be readily 
recognized by the reticuloendothelial system. Ceria ENMs larger than 5 nm were very 
rapidly cleared from circulating blood. All the ceria ENMs had a much greater Vdss than 
the cerium ion, consistent with their extensive distribution and prolonged retention 
throughout the rat. The 15 and 30 nm ceria ENMs showed concentration ratios 
increasing vs. cerium ion over 4 h after infusion.  The distribution of ceria ENMs 
between serum and the blood clot was size dependent.  The citrate-coated 30-nm ceria 
showed the greatest distribution in the clot fraction. The fraction of 15 and 30 nm-ceria 
ENMs in the clot fraction increased over 4 h, suggesting a change in their surface 
properties, perhaps due to opsonization. A further understanding of the rate and nature 
of ceria ENM association with blood proteins and cells, and the process(es) of their 





1. Batrakova EV, Kabanov AV: Pluronic block copolymers: evolution of drug 
delivery concept from inert nanocarriers to biological response modifiers. J 
Control Release 130(2), 98-106 (2008). 
2. Kanwar Jr, Mahidhara G, Kanwar RK: Recent advances in nanoneurology for 
drug delivery to the brain. Current Nanosci 5(4), 441-448 (2009). 
3. Karakoti AS, Monteiro-Riviere NA, Aggarwal R et al.: Nanoceria as antioxidant: 
synthesis and biomedical applications. JOM 60(3), 33-37 (2008). 
4. Tarnuzzer RW, Colon J, Patil S, Seal S: Vacancy engineered ceria 
nanostructures for protection from radiation-induced cellular damage. Nano Lett 
5(12), 2573-2577 (2005). 
5. Niu J, Azfer A, Rogers Lm, Wang X, Kolattukudy PE: Cardioprotective effects of 
cerium oxide nanoparticles in a transgenic murine model of cardiomyopathy. 
Cardiovasc Res 73(3), 549-559 (2007). 
6. Xia T, Kovochich M, Liong M et al.: Comparison of the mechanism of toxicity of 
zinc oxide and cerium oxide nanoparticles based on dissolution and oxidative 
stress properties. ACS Nano 2(10), 2121-2134 (2008). 
7. Schubert D, Dargusch R, Raitano J, Chan SW: Cerium and yttrium oxide 
nanoparticles are neuroprotective. Biochem Biophys Res Comm 342(1), 86-91 
(2006). 
8. Singh N, Cohen CA, Rzigalinski BA: Treatment of neurodegenerative disorders 
with radical nanomedicine. Ann N Y Acad Sci 1122, 219-230 (2007). 
9. D'angelo B, Santucci S, Benedetti E et al.: Cerium oxide nanoparticles trigger 
neuronal survival in a human Alzheimer disease model by modulating BDNF 
pathway Current Nanosci 5(2), 167-176 (2009). 
10. Chen J, Patil S, Seal S, Mcginnis JF: Rare earth nanoparticles prevent retinal 
degeneration induced by intracellular peroxides. Nat Nanotechnol 1(2), 142-150 
(2006). 
11. Das M, Patil S, Bhargava N et al.: Auto-catalytic ceria nanoparticles offer 
neuroprotection to adult rat spinal cord neurons. Biomaterials 28(10), 1918-1925 
(2007). 
12. Park EJ, Choi J, Park YK, Park K: Oxidative stress induced by cerium oxide 
nanoparticles in cultured BEAS-2B cells. Toxicology 245(1-2), 90-100 (2008). 
13. Thill A, Zeyons O, Spalla O et al.: Cytotoxicity of CeO2 nanoparticles for 
Escherichia coli. Physico-chemical insight of the cytotoxicity mechanism. Environ 
Sci Technol 40(19), 6151-6156 (2006). 
14. Brunner TJ, Wick P, Manser P et al.: In vitro cytotoxicity of oxide nanoparticles: 
comparison to asbestos, silica, and the effect of particle solubility. Environ Sci 
Technol 40(14), 4374-4381 (2006). 
15. Eom HJ, Choi J: Oxidative stress of CeO2 nanoparticles via p38-Nrf-2 signaling 
pathway in human bronchial epithelial cell, Beas-2B. Toxicol Lett 187(2), 77-83 
(2009). 
16. Lin W, Huang YW, Zhou XD, Ma Y: Toxicity of cerium oxide nanoparticles in 
human lung cancer cells. Int J Toxicol 25(6), 451-457 (2006). 
17. Park E-JC, Wan-Seob, Jeong J, Yi J-H, Choi K, Kim Y, Park K: Induction of 
inflammatory responses in mice treated with cerium oxide nanoparticles by 
intratracheal instillation. J Health Sci 56(4), 387-396 (2010). 
18. Yokel RA, Florence RL, Unrine JM et al.: Biodistribution and oxidative stress 
effects of a systemically-introduced commercial ceria engineered nanomaterial. 
Nanotoxicology 3(4), 234-248 (2009). 
19. Riviere JE: Pharmacokinetics of nanomaterials: an overview of carbon 
nanotubes, fullerenes and quantum dots. Wiley Interdiscip Rev Nanomed 
Nanobiotechnol 1(1), 26-34 (2009). 
20. Hardas SS, Butterfield DA, Sultana R et al.: Brain distribution and toxicological 
evaluation of a systemically delivered engineered nanoscale ceria. Toxicol Sci 
116(2), 562-576 (2010). 
21. Riddick TM: Control of colloidal stability through zeta potential. Livingston 
Publishing Co., Wynnewood, PA, pp 320-331 (1968). 
22. Gaur U, Sahoo SK, De TK, Ghosh PC, Maitra A, Ghosh PK: Biodistribution of 
fluoresceinated dextran using novel nanoparticles evading reticuloendothelial 
system. Int J Pharm 202(1-2), 1-10 (2000). 
23. Niidome T, Yamagata M, Okamoto Y et al.: PEG-modified gold nanorods with a 
stealth character for in vivo applications. J Control Release 114(3), 343-347 
(2006). 
24. Cao T, Yang T, Gao Y, Yang Y, Hu H, Li F: Water-soluble NaYF4:Yb/Er 
upconversion nanophosphors: Synthesis, characteristics and application in 
bioimaging. Inorg Chem Commun 13(3), 392-394 (2010). 
25. Frasca G, Gazeau F, Wilhelm C: Formation of a three-dimensional multicellular 
assembly using magnetic patterning. Langmuir 25(4), 2348-2354 (2009). 
26. Pallem VL, Stretz HA, Wells MJ: Evaluating aggregation of gold nanoparticles 
and humic substances using fluorescence spectroscopy. Environ Sci Technol 
43(19), 7531-7535 (2009). 
27. Brewer SH, Glomm WR, Johnson MC, Knag MK, Franzen S: Probing BSA 
binding to citrate-coated gold nanoparticles and surfaces. Langmuir 21(20), 
9303-9307 (2005). 
28. Masui T, Hirai H, Imanaka N, Adachi G, Sakata T, Mori H: Synthesis of cerium 
oxide nanoparticles by hydrothermal crystallization with citric acid. J Mat Sci Lett 
21(6), 489-491 (2002). 
29. Pan C, Zhang D, Shi L: CTAB assisted hydrothermal synthesis, controlled 
conversion and CO oxidation properties of CeO2 nanoplates, nanotubes, and 
nanorods. J Solid State Chem 181(6), 1298-1306 (2008). 
30. Mai H-X, Sun L-D, Zhang Y-W et al.: Shape-selective synthesis and oxygen 
storage behavior of ceria nanopolyhedra, nanorods, and nanocubes. J Phys 
Chem B  109(51), 24380-24385 (2005). 
31. Wu Q, Zhang F, Xiao P et al.: Great influence of anions for controllable synthesis 
of CeO2 nanostructures: From nanorods to nanocubes. J Phys Chem C 112(44), 
17076-17080 (2008). 
32. Zhang F, Jin Q, Chan S-W: Ceria nanoparticles: Size, size distribution, and 
shape. J Appl Phys 95(8), 4319-4326 (2004). 
33. Mandzy N, Grulke E, Druffel T: Breakage of TiO2 agglomerates in 
electrostatically stabilized aqueous dispersions. Powder Technol 160(2), 121-126 
(2005). 
34. Yokel RA, Au TC, MacPhail R et al.: Distribution, elimination and biopersistence 
to 90 days of a systemically-introduced 30 nm ceria engineered nanomaterial in 
rats. Nanotoxicology, (in preparation). 
35. Bjondahl K: Differences in liver weight, mortality in cerium-treated mice and 
144Ce levels in blood, liver, urine and faeces at various intervals after treatment 
with nafenopin and pregnenolone 16-alpha-carbonitrile (PCN). Medical Biol 
54(6), 454-460 (1976). 
36. Moskalev YI: [Experiments on distribution of Ce 144]. Med Radiol (Mosk) 4(5), 
52-58 (1959). 
37. Takada K, Fujita M: Effects of DTPA on the excretion and tissue distribution of 
144Ce administered subcutaneously, intramuscularly and intravenously in rats. J 
Radiat Res (Tokyo) 14(2), 187-197 (1973). 
38. Limbach LK, Li Y, Grass RN et al.: Oxide nanoparticle uptake in human lung 
fibroblasts: effects of particle size, agglomeration, and diffusion at low 
concentrations. Environ Sci Technol 39(23), 9370-9376 (2005). 
39. Rzigalinski BA, Danelison I, Strawn ET, Cohen CA, Liang C: Nanoparticles for 
cell engineering - A radical concept. In: Nanotechnologies for the Life Sciences, 
Kumar Cssr (Eds). Wiley-VCH, Hoboken, New Jersey 361-387 (2006). 
40. Rzigalinski BA, Meehan K, Davis RM, Xu Y, Miles WC, Cohen CA: Radical 
nanomedicine. Nanomedicine (Lond) 1(4), 399-412 (2006). 
41. Hirst SM, Karakoti AS, Tyler RD, Sriranganathan N, Seal S, Reilly CM: Anti-
inflammatory properties of cerium oxide nanoparticles. Small 5(24), 2848-2856 
(2009). 
42. He XA, Zhang HF, Ma YH et al.: Lung deposition and extrapulmonary 
translocation of nano-ceria after intratracheal instillation. Nanotechnology 21(28), 
(2010). 
43. Nakamura Y, Tsumura Y, Tonogai Y, Shibata T, Ito Y: Differences in behavior 
among the chlorides of seven rare earth elements administered intravenously to 
rats. Fundam Appl Toxicol 37(2), 106-116 (1997). 
44. Geiser M, Rothen-Rutishauser B, Kapp N et al.: Ultrafine particles cross cellular 
membranes by nonphagocytic mechanisms in lungs and in cultured cells. 
Environ Health Perspect 113(11), 1555-1560 (2005). 
45. Rothen-Rutishauser BM, Schurch S, Haenni B, Kapp N, Gehr P: Interaction of 
fine particles and nanoparticles with red blood cells visualized with advanced 
microscopic techniques. Environ Sci Technol 40(14), 4353-4359 (2006). 
46. Wang J, Zhou G, Chen C et al.: Acute toxicity and biodistribution of different 
sized titanium dioxide particles in mice after oral administration. Toxicol Lett 
168(2), 176-185 (2007). 
47. Yang RS, Chang LW, Wu JP et al.: Persistent tissue kinetics and redistribution of 
nanoparticles, quantum dot 705, in mice: ICP-MS quantitative assessment. 
Environ Health Perspect 115(9), 1339-1343 (2007). 
48. Al-Jamal WT, Al-Jamal KT, Cakebread A, Halket JM, Kostarelos K: Blood 
circulation and tissue biodistribution of lipid--quantum dot (L-QD) hybrid vesicles 
intravenously administered in mice. Bioconjug Chem 20(9), 1696-1702 (2009). 
49. Fischer HC, Liu L, Pang KS, Chan WCW: Pharmacokinetics of nanoscale 
quantum dots: in vivo distribution, sequestration, and clearance in the rat 
Advanced Functional Materials 16(10), 1299-1305 (2006). 
50. Li M, Al-Jamal KT, Kostarelos K, Reineke J: Physiologically based 
pharmacokinetic modeling of nanoparticles. ACS Nano 4(11), 6303-6317 (2010). 
51. Owens DE, Peppas NA: Opsonization, biodistribution, and pharmacokinetics of 
polymeric nanoparticles. Int J Pharm 307(1), 93-102 (2006). 
52. Deng ZJ, Mortimer G, Schiller T, Musumeci A, Martin D, Minchin RF: Differential 
plasma protein binding to metal oxide nanoparticles. Nanotechnology 20(45), 
455101/455101-455101/455109 (2009). 
53. Uren RF, Hoefnagel CA: Lymphoscintigraphy. In: Textbook of melanoma, 
Thompson JF, Morton DL, Kroon BBR (Eds). Martin Dunitz, New York 339-364 
(2004). 
54. Kim S, Lim YT, Soltesz EG et al.: Near-infrared fluorescent type II quantum dots 
for sentinel lymph node mapping. Nat Biotechnol 22(1), 93-97 (2004). 
55. Yokel RA, Tseng MT, Dan M et al.: Distribution and biopersistence of ceria 
engineered nanomaterial in rats - influence of size. Toxicology, (in preparation). 
56. Rowland M, Tozer TN: Clinical pharmacokinetics and pharmacodynamics: 
Concepts and applications, 4th Ed.  Wolters Kluwer, Philadelphia, (2011). 
57. Distefano JJ: Noncompartmental vs. compartmental analysis: some bases for 
choice. Am J Physiol 243(1), R1-6 (1982). 
58. Yang RS, Chang LW, Yang CS, Lin P: Pharmacokinetics and physiologically-
based pharmacokinetic modeling of nanoparticles. J Nanosci Nanotechnol 
10(12), 8482-8490 (2010). 
59. Li M, Al-Jamal KT, Kostarelos K, Reineke J: Physiologically based 
pharmacokinetic modeling of nanoparticles. ACS Nano 4(11), 6303-6317 (2010). 
60. Li SD, Huang L: Pharmacokinetics and biodistribution of nanoparticles. Mol 
Pharm 5(4), 496-504 (2008). 
61. Nyland JF, Silbergeld EK: A nanobiological approach to nanotoxicology. Hum 
Exp Toxicol 28(6-7), 393-400 (2009). 
62. Lee HA, Leavens TL, Mason SE, Monteiro-Riviere NA, Riviere JE: Comparison 
of quantum dot biodistribution with a blood-flow-limited physiologically based 
pharmacokinetic model. Nano Lett 9(2), 794-799 (2009). 
 
101. Health Effects Institute: Evaluation of human health risk from cerium added to 
diesel fuel, Communication 9, Boston, MA, 
http://pubs.healtheffects.org/getfile.php?u=295. 
102. Integrated Laboratory Systems, Inc.: Chemical information profile for ceric oxide 
[CAS No. 1306-38-3]. Supporting Nomination for Toxicological Evaluation by the 
National Toxicology Program, 21pp, 
http://ntp.niehs.nih.gov/index.cfm?objectid=0847DDA0-F261-59BF-
FAA04EB1EC032B61. 
103. Environment Directorate, Joint Meeting of the Chemicals Committee and the 
Working Party on Chemicals, Pesticides and Biotechnology, Organisation for 
Economic Co-operation and Development: List of manufactured nanomaterials 
and list of endpoints for phase one of the sponsorship programme for the testing 
of manufactured nanomaterials: revision, Series on the safety of manufactured 




** = of considerable interest [19] Riviere. This is a review of carbon-based and quantum 
dot ENM pharmacokinetics.  
 
Financial disclosure and conflict of interest declaration: 
None of the authors has a financial conflict of interest related to this research. No writing 
assistance was obtained in the preparation of this report.  
 
Funding: This work was supported by the United States Environmental Protection 
Agency Science to Achieve Results [Grant Number RD-833772].  
 
Acknowledgements: The authors gratefully acknowledge Rebecca L. Florence for her 
excellent conduct of aspects of this work and Dr. Robert C. MacPhail for his critical and 
constructive review of a draft of this report. 
  
Figure legends. 
Figure 1. HRTEM and STEM images of ceria used in this study:  (a) TEM/STEM: 5-nm 
polyhedral ceria; (b) TEM: 15-nm polyhedral ceria; (c) TEM: 30-nm cubic ceria; (d) TEM: 
30-nm cubic and rod ceria; (e) STEM: 55-nm polyhedral ceria.  
 
Figure 2. Whole blood Ce concentration after completion of iv infusion of the cerium ion, 
5, 15, and 30 ceria ENM, a mixture of 30-nm ceria cubes and rods, and 55-nm ceria 
ENM. All values are normalized to an equivalent dose of 100 mg ceria/kg. Results are 
mean ± S.D. from 5 rats at each time point, except for cerium ion, where n = 3 for 5 nm 
ceria ENM where n = 9, 10, 21, 10, 12, and 7 rats at 0.167, 0.5, 1, 2, 20 and 720 h; for 
15 nm ceria ENM where n = 10 rats at 0.167, 0.5, 1, 2, and 4 h; for 30 nm ceria ENM 
were n = 6 for al times except 1, 20 168 and 720 h where n = 10, 8, 3 and 11; and for 
the 55 nm ceria ENM were n = 10 and 7 at 1 and 20 h, respectively.  The horizontal line 
at the top of each graph shows the calculated cerium concentration in blood 
representing 100% of the dose.   
 
Figure 3. The ratio of Ce concentration in whole blood following iv infusion of 5-, 15-, 30- 
and 55-nm ceria ENMs from 0.167 to 4 h after their infusion, compared to the cerum ion 
concentration. Each symbol represents a different rat. 
 
Figure 4. The ratio of cerium in serum to whole blood (as %), following iv infusion of the 
cerium ion; 5-, 15-, and 30-nm ceria ENMs; mixture of 30-nm cubic + rod ceria ENMs; 
and 55-nm ceria ENM. Each symbol shows results from a different rat. For the 15-nm 
ceria ENM the solid curve is the model for the rat shown by the open circle, dashed line 
for rat shown by the closed square, and double curve for rat shown by the closed 
diamond. For the 30-nm ceria ENM the solid curve is the model for the rat shown by the 
closed square, dashed line for rat shown by the open circle, double curve for rat shown 
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Table 1. Physico-chemical properties of the ceria ENMs. Shape delineation based on 
TEM data. Dave (average primary particle diameter from number frequency distribution) 
and standard deviation based on TEM measurements of diameter fitted using lognormal 
distribution models. Citrate loading expressed as % of monolayer coverage (TGA 








[TEM, Lognormal model] 
zeta potential 
in water at 




5 polyhedral 4.6 (0.135) - 53 ± 7 ~ 40% 
15 polyhedral 12.0 (0.232) - 57 ± 5 ~ 27% 
30 cubic 31.2 (0.478) - 56 ± 8 ~ 18% 
55 polyhedral 55 (0.162) - 32 ± 2* ~ 15%* 




Table 2. Pharmacokinetic parameters for the cerium ion; 5-, 15-, 30- and 55-nm ceria ENMs; and mixture of 30-nm cubic 
and rod ceria ENMs and after iv infusion to rats. Values are means ± SD, calculated from results obtained from times 
shown (after completion of the infusion).  
 0.167 h to 7 days 0.167 h to 30 days   0.167 to 4 h 





  30-nm cubic + 
rods ceria (n=5) 
55 nm ceria 
(n=5) 
Non-compartmental Analysis 
AUC (h* mg/L) 326 ± 102a 2264 ± 1284b 361 ± 130a 2201 ± 1314b   25 ± 8a 1.5 ± 0.5a 
Cmax (mg/L) 163 ± 27a 278 ± 215b 0.95 ± 0.34a 6.5 ± 3.1a   20 ± 11a 0.78 ± 0.12a 
t1/2 (h) 2.7 ± 0.8a 80 ± 25b - -   26 ± 36a 2.2 ± 0.8a 
MRT (h) 1.5 ± 0.2a 7.1 ± 3.0a 41 ± 11b 15 ± 11a   1.6 ± 1.8a 1.5 ± 0.1a 
 Two Compartment Model  One Compartment Model 
AUC (h* mg/L) 1377 ± 416c 690 ± 181a 152 ± 41b 561 ± 256a   72 ± 39b 1.9 ± 0.7b 
Cmax (mg/L) 190 ± 29a,b 372 ± 317a 0.82 ± 0.45b 3.5 ± 1.7b   12 ± 5b 0.88 ± 0.44b 
t1/2-α (h) 0.57 ± 0.13 0.44 ± 0.27 2.5 ± 2.6 12 ± 17   4.3 ± 1.8 1.9 ± 0.6 
t1/2-β (h) 16 ± 3b 124 ± 53a,b 239 ± 56c 140 ± 43a   - - 
MRT (h) 21 ± 3c 92 ± 53a,c 343 ± 83b 192 ± 57a   6.3 ± 2.6c 2.8 ± 0.8c 
CL (L/h/kg) 0.078 ± 0.028a 0.15 ± 0.04a 0.71 ± 0.24a 0.22 ± 0.11a   1.4 ± 1.0a 46 ± 30b 
Vdss (L/kg) 1.7 ± 0.8a 15 ± 12a 240 ± 8b 38 ± 12a   9.6 ± 3.9a 130 ± 42c 
AUC, area under the concentration–time curve; t1/2-α , first half-life; t1/2-β , second half-life; Cmax, peak concentration; CL, 
Clearance; MRT, mean residence time;  Vdss, volume of distribution at steady state. 
57 
 
*  For each parameter, results that do not have the same superscript letters are statistically significantly different by post 




Table 3. The whole blood compartment model, serum and clot partitioning, and ceria 
ENM vs. cerium ion ratio results of the six materials studied.  









Cerium ion Fits the two compartment model Not applicable 
No strong 
trend  
5 nm ceria 
Fits the two compartment 
model; longer persistence in 
the second compartment than 
the cerium ion 
Time-dependent 
reduction in [Ce] 
relative to the ion; 




15 nm ceria 
Rapid loss during infusion; 
Apparent re-distribution to 
blood in 2-4 hours 
Increase relative to 









30 nm ceria 
Rapid loss during infusion; 
Apparent re-distribution to 
blood in 2-4 hours 
Increase relative to 









Cubic + rod ceria 
Loss during infusion; 
Apparent redistribution to 
blood in 2-4 hours   
No strong trend 
No strong 
trend; less 
than 50% in 
serum 
 
55 nm ceria 
Rapid loss during infusion; No 
apparent re-distribution to 
whole blood in 2-4 hours 
No strong trend No strong trend  
 
